Translational Demonstration – HemeChip: An Automated Portable Microchip Electrophoresis Platform for Point-of-Care Sickle Cell Disease Screening

Umut A. Gurkan1, Peter Galen2

  • 1Case Western Reserve University
  • 2Hemex Health

Details

12:00 - 13:45 | Mon 6 Nov | Auditorium Foyer, E1/E2, Upper Atrium Space | MLunch_Break.36

Session: Lunch, Posters and POC Technologies Demonstrations – Session I

Abstract

Sickle Cell Disease (SCD) affects more than 14 million people globally, primarily in economically disadvantaged populations. Its management requires early diagnosis, monitoring, and treatment throughout the lifespan of the patient. Early diagnosis of SCD remains a challenge in the developing world due to requirements for sophisticated lab equipment and skilled personnel. American Society of Hematology with other organizations launched the Sickle Cell Disease Coalition, calling for improved patient care. In low-income countries, notably those in Sub-Saharan Africa, the mortality rate for children